Application of cimicifugin in pharmacy
A technology for the use of cimichin, which is applied in the field of medical use of cimichin, and can solve the problems of not being able to reduce recurrence and change the pathological process of allergic diseases
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0038] Method: BALB / c mice, male, weighing 18-22g, were randomly divided into 5 groups, 8 mice in each group, including blank, model, dexamethasone, and cimichin 12.5 mg·kg -1 , 50mg·kg -1 Group. The intraperitoneal injection dose of dexamethasone is 0.67mg·kg -1 , 0.1ml / 10g. The cimichin group was intragastrically administered, and the blank group and the model group were intragastrically administered equal volumes of normal saline. The mice in each group were administered from the -1st day of sensitization to the third day, once a day, a total of 5 times (this is the initial sensitization administration). BALB / c mice were sensitized by applying 20 μL of 0.5% FITC solution (solvent: acetone: butylene phthalate 1:1) to both ears on the first day and the second day, and after 24 hours, the ear tissues were collected and analyzed. Preparation of Homogenate. The levels of cytokines TSLP and IL-33 were measured by ELISA method, and the total protein level was measured by BCA ...
Embodiment 2
[0045] Methods: BALB / c mice, male body weight 18-22g, were randomly divided into 5 groups, namely blank group, model group, dexamethasone (0.67mg·kg -1 ), Cimicifume (12.5mg·kg -1 ), Cimicifume (50mg·kg -1 ). Intraperitoneal injection of dexamethasone, intragastric administration of cimiculin group, intragastric administration of equal volume of normal saline in the blank group and model group. The mice in each group were administered from the sensitization day -1 to the third day, once a day, 5 times in total, and the mice were coated with 0.5% FITC solution (solvent: acetone: Butylene phthalate (1:1) was sensitized with 20 μL, and after 24 hours, ear tissues were collected. The expression of TSLP and IL-33mRNA in ear tissues was determined by RT-PCR.
[0046] Result: Cimicifume 12.5mg·kg -1 , 50mg·kg -1 group can significantly reduce the level of TSLPmRNA in the homogenate of the ear tissue of the modeled mice, and Cimicibutin 50mg·kg -1 group can significantly reduce...
Embodiment 3
[0052] Method: HaCaT cells were cultured normally, and after the cells were congested, the plate was seeded according to 1×105. Sterilized glass slides are pre-placed in the 24-well plate for cell climbing. Pre-incubated with cimichine for 6 hours, then combined stimulation with Poly(I:C) 100ug / ml+TNF-α 20ng / ml after 6 hours, and collected cell supernatant and slides after 12 hours. Immunofluorescence experiments were performed to detect the expression levels of TSLP and IL-33 on the slides, and the levels of TSLP and IL-33 were detected by ELISA in the cell supernatant.
[0053] Results: ELISA results showed that the expression of TSLP was significantly increased after HaCaT cells were jointly stimulated by Poly(I:C) 100μg / ml+TNF-α20ng / ml. Cimicin 0.1 μM, 1 μM, and 10 μM significantly reduced the level of TSLP; immunofluorescence results also showed that the expression of TSLP was significantly enhanced after HaCaT cells were jointly stimulated by Poly(I:C) 100 μg / ml+TNF-α 2...
PUM
| Property | Measurement | Unit |
|---|---|---|
| The average particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More